Significance of IKZF1 deletions in pediatric ALL

Anthony Moorman, PhD, Newcastle University, Newcastle, UK talks on IKZF1 (Ikarus) deletions in pediatric acute lymphoblastic leukemia (ALL) and whether it is still a poor prognostic marker, taking in account genetic context and minimal residual disease (MRD) at the end of induction therapy. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).